- Info
- Portfolio
- Significant Ownership
- Insider Ownership
Significant Ownership of Paradigm Biocapital Advisors LP
- Signature - Title
- /s/ David K. Kim - David K. Kim / Authorized Signatory
- Location
- New York, NY
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by Paradigm Biocapital Advisors LP.
Follow Filing Activity
Follow Paradigm Biocapital Advisors LP and return when a new Schedule 13D/G filing appears.
This tracks SEC filing changes for this page using existing product update flows.
Continue schedule research
Related filing hubs for this reporting manager, useful for reinforcing crawl paths across the schedule cluster.
Significant Ownership of Paradigm Biocapital Advisors LP
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| OLMA | Olema Pharmaceuticals, Inc. | Common Stock, $0.0001 par value per share | 10% | $37,443,949 | 7,429,355 | Paradigm BioCapital Advisors LP | 31 Dec 2024 | ||
| ACLX | Arcellx, Inc. | Common Stock, $0.001 par value per share | 9.9% | $379,330,540 | 5,724,016 | Paradigm BioCapital Advisors LP | 31 Dec 2025 | ||
| URGN | UroGen Pharma Ltd. | Ordinary Shares, par value NIS 0.01 per share | 9% | $84,110,876 | +$37,586,159 | 4,216,084 | +81% | Paradigm BioCapital Advisors LP | 30 Sep 2025 |
| LXEO | Lexeo Therapeutics, Inc. | Common Stock, $0.0001 par value per share | 6.5% | $35,390,561 | +$8,107,609 | 4,763,198 | +30% | Paradigm BioCapital Advisors LP | 31 Dec 2025 |
| EWTX | Edgewise Therapeutics, Inc. | Common Stock, $0.0001 par value per share | 6.2% | $161,371,651 | +$44,462,272 | 6,541,210 | +38% | Paradigm BioCapital Advisors LP | 31 Dec 2025 |
| MAZE | Maze Therapeutics, Inc. | Common Stock, $0.001 par value per share | 6.1% | $155,788,502 | 3,051,087 | Paradigm BioCapital Advisors LP | 25 Mar 2026 | ||
| ERAS | Erasca, Inc. | Common Stock, $0.0001 par value per share | 5.3% | $56,391,833 | 15,159,095 | Paradigm BioCapital Advisors LP | 07 Jan 2026 | ||
| EYPT | EyePoint, Inc. | Common Stock, $0.001 par value per share | 5.1% | $64,770,432 | 4,192,261 | Paradigm BioCapital Advisors LP | 17 Feb 2026 | ||
| AGIO | Agios Pharmaceuticals, Inc. | Common Stock, $0.001 par value per share | 4.9% | $115,344,498 | -$6,198,499 | 2,873,555 | -5.1% | Paradigm BioCapital Advisors LP | 30 Sep 2025 |
| JANX | Janux Therapeutics, Inc. | Common Stock, $0.001 par value per share | 4.9% | $73,444,489 | -$14,982,559 | 2,920,258 | -17% | Paradigm BioCapital Advisors LP | 30 Jun 2025 |
| VOR | VOR Biopharma Inc. | Common Stock, $0.0001 par value per share | 4.5% | $23,730,000 | 1,750,000 | 0% | Paradigm BioCapital Advisors LP | 31 Dec 2025 | |
| LENZ | LENZ Therapeutics, Inc. | Common Stock, $0.00001 par value per share | 3.8% | $50,001,813 | -$16,133,961 | 1,073,461 | -24% | Paradigm BioCapital Advisors LP | 30 Sep 2025 |
| IRON | Disc Medicine, Inc. | Common Stock, $0.0001 par value per share | 3.5% | $57,097,283 | 1,210,971 | Paradigm BioCapital Advisors LP | 31 Mar 2025 | ||
| CDTX | Cidara Therapeutics, Inc. | Common Stock, $0.0001 par value per share | 3.3% | $92,041,065 | -$16,034,916 | 961,164 | -15% | Paradigm BioCapital Advisors LP | 30 Sep 2025 |
| COGT | Cogent Biosciences, Inc. | Common Stock, $0.001 par value per share | 2.3% | $45,325,875 | -$103,335,292 | 3,156,398 | -70% | Paradigm BioCapital Advisors LP | 30 Sep 2025 |
| YMAB | Y-mAbs Therapeutics, Inc. | Common Stock, $0.0001 par value per share | 0% | $0 | 0 | Paradigm BioCapital Advisors LP | 30 Sep 2025 | ||
| MRUS | Merus N.V. | Common Shares, (euro)0.09 nominal value per share | 0% | $0 | -$420,639,300 | 0 | -100% | Paradigm BioCapital Advisors LP | 31 Dec 2025 |
| KURA | Kura Oncology, Inc. | Common Stock, $0.0001 par value per share | 0% | $0 | 0 | Paradigm BioCapital Advisors LP | 31 Dec 2024 | ||
| PLRX | Pliant Therapeutics, Inc. | Common Stock, $0.0001 par value per share | 0% | $0 | 0 | Paradigm BioCapital Advisors LP | 31 Mar 2025 |
Schedules 13D/G Reported by Paradigm Biocapital Advisors LP:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.